(Q43792942)

26 November 2017

Oral ciprofloxacin therapy of infections due to Pseudomonas aeruginosa (English)

1 reference

26 November 2017

Pseudomonas aeruginosa

0 references

author name string

B E Scully

1

1 reference

26 November 2017

H C Neu

2

1 reference

26 November 2017

M F Parry

3

1 reference

26 November 2017

W Mandell

4

1 reference

26 November 2017

language of work or name

English

0 references

publication date

1 April 1986

1 reference

26 November 2017

1 reference

26 November 2017

1

1 reference

26 November 2017

819-822

1 reference

26 November 2017

8485

1 reference

In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents

26 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2886%2990937-2

7 January 2021

Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2886%2990937-2

7 January 2021

The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2886%2990937-2

7 January 2021

Pharmacokinetics and tissue penetration of ciprofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2886%2990937-2

7 January 2021

In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2886%2990937-2

7 January 2021

In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2886%2990937-2

7 January 2021

Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2886%2990937-2

7 January 2021

Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2886%2990937-2

7 January 2021

Use of aztreonam in the treatment of serious infections due to multiresistant gram-negative organisms, including Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2886%2990937-2

7 January 2021

10.1016/S0140-6736(86)90937-2

Identifiers

DOI

1 reference

26 November 2017

1 reference